2018
DOI: 10.1016/j.jval.2018.04.1342
|View full text |Cite
|
Sign up to set email alerts
|

Cost-Effectiveness of Tofacitinib in Patients with Rheumatoid Arthritis in China

Abstract: s197 important implication that the new treatment sarilumab (KEVZARA) may be more cost-effective when compared to adalimumab (HUMIRA) for treating patients with rheumatoid arthritis.

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles